Clinical Trial Update: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the impact of a PCSK9-binding antibody on cognitive health in high cardiovascular risk subjects with dyslipidemia has completed; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Dyslipidemia

Drugs mentioned

• PCSK9-binding antibody

Snippet

Sponsor: Amgen | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED | Results posted: 2018-01-16